As we look forward to 2019, the hospital/health system M&A market is increasingly becoming a bifurcated landscape of clear “haves” and “have-nots”.
On December 27, 2018, the United States District Court for the District of Columbia granted a permanent injunction on the 2018 Medicare reimbursement cuts related to 340B drugs. What does this mean for the hospitals affected by these changes?
The Centers for Medicare & Medicaid Services (CMS) finalized key updates to the Medicare Hospital Outpatient Prospective Payment System (OPPS), the Ambulatory Surgical Center Payment System (ASCPS), and the Physician Fee Schedule (PFS) that will be effective January 1, 2019, with additional changes to be implemented in 2021.
On October 25, President Trump announced his plan to lower prescription drug prices. Under the plan’s new proposed payment system, the Centers for Medicare & Medicaid Services (CMS) will launch a five-year pilot program—the International Pricing Index (IPI) model—that will allow Medicare to pay less for select Part B drugs when a lower international price is available.
CMS is expected to announce the final payment rules for ASCs in the next few weeks. Here are four key changes to look for when the final rules are published in November:
In the final rule for the fiscal year 2019 update to the inpatient prospective payment system, effective August 17, 2018, CMS announced a new round of applications due to the closure of Memorial Hospital of Rhode Island. This is only the 13th round of section 5506 cap space reallocation since passage of the PPACA.
A new teaching hospital exception allows hospitals that were not training residents as of 1996 to establish a new resident cap, increasing the total number of Medicare-funded residency slots across the country.
Last Friday, President Trump, with the help of Health and Human Services Secretary Alex Azar, unveiled the administration’s “Blueprint to Lower Drug Prices.” As this issue was a central tenet of President Trump’s 2016 campaign platform, guidance on the administration’s approach to tackling drug prices has long been anticipated.
Prescription drugs have long been one of the greatest plagues on the country’s healthcare costs. While this issue has garnered attention for decades, the drug debate has a renewed vigor in Washington since President Trump unveiled his “Blueprint to Lower Drug Prices” last week.
Page 1 of 8